Polymer modified C3N4 nano-particles and preparation method and pharmaceutical application thereof

By using a polymer-modified C3N4 nanoparticle preparation method, the problem of poor stability of C3N4 nanoparticles was solved, achieving stability and copper ion adsorption capacity in the gastrointestinal tract, thus providing an effective treatment for Wilson's disease.

CN118903449APending Publication Date: 2024-11-08ZHUHAI PEOPLES HOSPITAL GUANGDONG PROVINCE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410878539.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The poor stability of C3N4 nanoparticles limits their effectiveness in drug applications, especially in the treatment of copper metabolism disorders such as Wilson's disease, where traditional drugs like D-penicillamine have many adverse reactions and limited efficacy.

Method used

By modifying C3N4 nanoparticles with polymers such as hyaluronic acid, polymer-modified C3N4 nanoparticles with an average particle size of 120-130 nm were prepared by stirring and centrifugation, thereby improving their stability in the gastrointestinal tract and their copper ion adsorption capacity.

Benefits of technology

The stability and biocompatibility of C3N4 nanoparticles are enhanced, enabling them to effectively adsorb copper ions in the body, reduce the concentration of copper ions in the liver, reduce liver damage, and provide a safer oral medication option for the treatment of Wilson's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903449A_ABST
    Figure CN118903449A_ABST
Patent Text Reader

Abstract

The invention discloses a polymer modified C3N4 nano-particle as well as a preparation method and medicinal application thereof. The preparation method comprises the following steps: mixing hyaluronic acid and C3N4 by taking water as a medium; and carrying out solid-liquid separation to obtain a solid which is the polymer modified C3N4 nano-particles. The preparation method is simple, and the obtained nanoparticles can improve the stability of C3N4 in gastrointestinal tracts and the oral bioavailability of C3N4; and through oral administration, copper ions in the body can be adsorbed, the copper ion concentration of the liver can be effectively reduced, the injury effect of the copper ions on the liver can be weakened, hepatolenticular degeneration diseases can be treated, and the hepatotoxicity of the traditional medicine penicillamine can be overcome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the medical field, and in particular relates to a polymer-modified C3N4 nanoparticle, a preparation method and a pharmaceutical use thereof. Background Art

[0002] Hepatolenticular degeneration is a copper metabolism disorder caused by mutations in the copper transporter ATPase β (ATP7B) gene. It can occur at any age, but is more common in children and adolescents. D-penicillamine is the first choice for oral treatment of hepatolenticular degeneration, but it has many adverse reactions, such as early allergic reactions, worsening of neurological symptoms, renal toxicity and skin toxicity, and about 30% of patients stop taking the drug due to adverse reactions.

[0003] As a member of the carbon nitride family, C3N4 has attracted extensive attention due to its unique optical and electrical properties, non-toxicity, degradability, cost-effectiveness and excellent biocompatibility. However, the poor stability of C3N4 limits its application. Summary of the invention

[0004] The primary purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and to provide a method for preparing polymer-modified C3N4 nanoparticles.

[0005] Another object of the present invention is to provide polymer-modified C3N4 nanoparticles obtained by the above preparation method.

[0006] Another object of the present invention is to provide an application of the above-mentioned polymer-modified C3N4 nanoparticles.

[0007] The purpose of the present invention is achieved by the following technical solution: A method for preparing polymer-modified C3N4 nanoparticles, comprising the following steps:

[0008] (1) Using water as a medium, hyaluronic acid and C3N4 are mixed;

[0009] (2) Solid-liquid separation, the solid obtained is polymer-modified C3N4 nanoparticles.

[0010] The above preparation method further comprises the following steps:

[0011] (3) The solid obtained in step (2) is washed with water and separated into solid and liquid, and the obtained solid is polymer-modified C3N4 nanoparticles.

[0012] The hyaluronic acid and C3N4 described in step (1) are preferably mixed in a mass ratio of 4 to 6:2; more preferably in a mass ratio of 5:2.

[0013] The water described in step (1) is preferably deionized water.

[0014] The amount of water used in step (1) is preferably calculated based on a ratio of 8-12 mL:50 mg of water to hyaluronic acid; more preferably, the amount of water used is calculated based on a ratio of 10 mL:50 mg of water to hyaluronic acid.

[0015] The mixing in step (1) is preferably stirred for 8 to 16 hours.

[0016] The stirring speed is preferably 400-600 rpm, more preferably 500 rpm.

[0017] The solid-liquid separation method in step (2) is preferably centrifugation.

[0018] The centrifugal condition is preferably 10000-12000 rpm for 15-30 min.

[0019] The water described in step (3) is preferably ultrapure water.

[0020] The number of washings in step (3) is preferably 1 to 3 times.

[0021] The solid-liquid separation method in step (3) is preferably centrifugation.

[0022] The centrifugal speed is preferably 10000-12000 rpm.

[0023] A polymer-modified C3N4 nanoparticle is obtained by the above preparation method; its average particle size is 120-130nm.

[0024] Application of the polymer-modified C3N4 nanoparticles in the preparation of drugs for treating copper metabolism disorders.

[0025] The copper metabolism disorder is preferably hepatolenticular degeneration.

[0026] Compared with the prior art, the present invention has the following advantages and effects:

[0027] (1) The nanoparticles obtained by modifying C3N4 with hyaluronic acid provided by the present invention improve the stability of C3N4 in the gastrointestinal tract and its oral bioavailability.

[0028] (2) The polymer-modified C3N4 nanoparticles provided by the present invention can be taken orally to adsorb copper ions in the body, effectively reduce the copper ion concentration in the liver, weaken the damaging effect of copper ions on the liver, treat Wilson's disease, and overcome the hepatotoxicity of the traditional drug penicillamine. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1It is a test result diagram of polymer-modified C3N4 nanoparticles; wherein A is the test result of hydrated particle size, B is the test result of surface potential, and C is the test result of stability in an acidic environment.

[0030] Figure 2 These are the test results of the copper adsorption capacity of polymer-modified C3N4 nanoparticles.

[0031] Figure 3 are the safety test results of polymer-modified C3N4 nanoparticles; wherein, A is the effect of CuCl2 on normal hepatocytes, B is the effect of different concentrations of C3N4, HA@C3N4, PEI@C3N4 and PEG@C3N4 on normal hepatocytes; C is the result of different concentrations of C3N4, HA@C3N4, PEI@C3N4 and PEG@C3N4 reversing the effect of CuCl2 on normal hepatocytes.

[0032] Figure 4 It is a diagram of the in vivo treatment results of polymer-modified C3N4 nanoparticles; wherein, A is the effect of polymer-modified C3N4 nanoparticles on the copper ion content in mouse blood, B is the effect of polymer-modified C3N4 nanoparticles on the copper ion content in mouse liver, and C is the protective effect of polymer-modified C3N4 nanoparticles on mouse liver damage; WT represents wild-type mice, and KO represents ATP7B gene knockout mice. DETAILED DESCRIPTION

[0033] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0034] Example 1

[0035] (1) Preparation of polymer-modified C3N4 nanoparticles

[0036] 50 mg of hyaluronic acid HA (40-100 KDa, McLean) and 20 mg of C3N4 (Cat. No.: 100547, Jiangsu Xianfeng Nanomaterial Technology Co., Ltd.) were dispersed in 10 mL of water and stirred at 500 rpm overnight; after the reaction was completed, the mixture was centrifuged at 12000 rpm for 20 minutes and the supernatant was removed; the precipitate was washed 3 times with ultrapure water and centrifuged (12000 rpm for 20 minutes) for solid-liquid separation; the solid was resuspended in 10 mL of ultrapure water and the obtained solution was named HA@C3N4.

[0037] According to the above method, polyethylene glycol PEG (MW: 10000-20000, McLean) was used to replace hyaluronic acid HA to obtain PEG@C3N4.

[0038] According to the above method, polyethyleneimine PEI (MW: 10000, McLean) was used to replace hyaluronic acid HA to obtain PEI@C3N4.

[0039] (2) Characterization of polymer-modified C3N4 nanosystems

[0040] Nano-ZS (Malvern Instruments Limited) was used to characterize the hydrated particle size and surface potential of C3N4, HA@C3N4, PEI@C3N4 and PEG@C3N4. 5 mg of C3N4, HA@C3N4, PEI@C3N4 and PEG@C3N4 were incubated in 10 mL of artificial gastric juice (commercially available) at pH = 2 for 48 hours, and the UV spectra were measured at various time points (0.5, 1, 2, 4, 8, 12, 24, 48 hours), and the degradation rate was calculated based on the absorbance at 280 nm.

[0041] The results are as follows Figure 1 As shown: Figure 1 A in the figure shows that the particle sizes of C3N4, HA@C3N4, PEI@C3N4, and PEG@C3N4 are 113.7 nm, 127.5 nm, 184.1 nm, and 131.1 nm, respectively; Figure 1 B in the figure shows that the surface potentials of C3N4, HA@C3N4, PLGA@C3N4, and PEG@C3N4 are -0.39 mV, -35.7 mV, 31.8 mV, and 1.3 mV, respectively; Figure 1 The C in the graph shows that the introduction of HA improves the stability of C3N4 in an acidic environment. The degradation rate of HA@C3N4 after immersion in an acidic solution for 48 hours is reduced from 67.7% to 28.5%. PEI@C3N4 has the best stability, with only 20.0% degradation in 48 hours. PEG@C3N4 degraded 49.4% in 48 hours. The results show that polymer modification can improve the stability of C3N4, especially PEI@C3N4 modification has the best stability.

[0042] (3) Copper ion adsorption capacity of polymer-modified C3N4 nanosystem

[0043] 5 mg of C3N4, HA@C3N4, PEI@C3N4 and PEG@C3N4 were taken and incubated in 10 mL of 10 mM CuCl2 solution (solvent: ultrapure water) for different time periods (5, 10, 20, 40 and 60 minutes). At different time points, 1 mL of the mixed solution was mixed and centrifuged at 12000 rpm for 10 minutes. The precipitate was digested and the copper ion concentration was measured by ICP-MS. The results are shown in Figure 2. Figure 2As shown, the results show that the introduction of polymers can improve the absorption capacity of C3N4 for copper ions, among which the PEI-modified nanosystem has the strongest absorption of copper ions. After 60 minutes of adsorption, the adsorption capacities of C3N4, HA@C3N4, PEI@C3N4 and PEG@C3N4 for copper ions are 14.9, 34.2, 36.0 and 26.2 mmol / g, respectively. Among them, HA@C3N4 and PEI@C3N4 both have good copper ion adsorption capacity.

[0044] (4) Safety of polymer-modified C3N4 nanosystems and their effects on reversing copper damage

[0045] Cytotoxicity experiment of cupric chloride: BNL.CL2 mouse normal hepatocytes (ATCC, USA) were transplanted into a 96-well plate at a rate of 2000 cells / well. After 24 hours, different concentrations of cupric chloride solution (0.1, 0.2, 0.4, 0.8, 1.6 and 3.2 mM) were added, 100 μL per well. After 72 hours, 25 μL of MTT solution (5 mg / mL) was added and incubated for 4 hours. Then, the culture medium was removed and 150 μL of DMSO solution was added, and the absorbance at 490 nm was measured.

[0046] Cytotoxicity experiment of polymer-modified C3N4 nanosystem: BNL.CL2 normal hepatocytes were transplanted into a 96-well plate at a rate of 2000 cells / well. After 24 hours, different concentrations of C3N4, HA@C3N4, PEI@C3N4 and PEG@C3N4 (8, 16, 32, 64, 128 and 256 μg / mL) were added, 100 μL per well. After 72 hours, 25 μL of MTT solution (5 mg / mL) was added and incubated for 4 hours. Then, the culture medium was removed and 150 μL of DMSO solution was added to measure the absorbance at 490 nm.

[0047] Polymer-modified C3N4 reverses copper damage experiment: BNL.CL2 normal hepatocytes were transplanted into a 96-well plate at 2000 cells / well. After 24 hours, different concentrations of C3N4, HA@C3N4, PEI@C3N4 and PEG@C3N4 (16 μg / mL) were added, 100 μL per well, and incubated for 4 hours; the culture medium was removed and treated with different concentrations of copper chloride solution (40, 80 and 160 μM), 100 μL per well; after 72 hours, 25 μL MTT solution (5 mg / mL) was added and incubated for 4 hours, then the culture medium was removed and 150 μL DMSO solution was added, and the absorbance at 490 nm was measured.

[0048] The results are as follows Figure 3 As shown: Figure 3A in the figure shows that the survival rate of normal liver cells of BNL.CL2 mice treated with CuCl2 decreases with the increase of copper ion concentration. When the copper ion concentration reaches 3.2 μM, the survival rate of BNL.CL2 cells is only 11.2%, which shows that CuCl2 has certain biological toxicity to BNL.CL2 cells. Figure 3 B in the figure shows that after treatment with C3N4, HA@C3N4 and PEG@C3N4, the survival rate of BNL.CL2 cells did not change significantly. After treatment with 256μg / mL of C3N4, HA@C3N4 and PEG@C3N4, the survival rates of BNL.CL2 cells were 94.3%, 92.3% and 94.7%, respectively. It can be seen that the C3N4, HA@C3N4 and PEG@C3N4 nanosystems have high biosafety, while after treatment with PEI@C3N4 nanosystem, the survival rate of BNL.CL2 cells decreased significantly. After treatment with 256μg / mL of PEI@C3N4, the survival rate of BNL.CL2 cells decreased to 66.5%, which shows that the biosafety of PEI@C3N4 nanosystem is low. Figure 3 C in the figure shows that C3N4, HA@C3N4, PEI@C3N4 and PEG@C3N4 treatment can reduce the toxicity of CuCl2, and the cell survival rate of BNL.CL2 cells is improved, especially the cell survival rate of HA@C3N4 treatment group (CuCl2 concentration is 80μM) increased from 69.3% to 81.4%, at this time, the cell survival rate of PEI@C3N4 treatment group is 73%; at 160μM, the cell survival rates of PEI@C3N4, HA@C3N4 and PEG@C3N4 are 36.5%, 55% and 46.6%, respectively. It can be seen that HA@C3N4 has high biosafety and can effectively reduce the harm of copper ions to cells.

[0049] (3) In vivo copper ion scavenging ability of polymer-modified C3N4 nanosystem

[0050] ATP7B knockout mice (purchased from Saiye (Suzhou) Biotechnology Co., Ltd.) were used as a model to simulate hepatolenticular degeneration, and the copper ion scavenging ability of C3N4 and HA@C3N4 was studied by oral administration. The drugs were administered once a day for four consecutive weeks, and all groups had normal drinking water and diet. C3N4 and HA@C3N4 groups were gavaged at 0.1g / kg; the wild-type group (BALB / c) and the model group (i.e., ATP7B knockout mice) were given an equal amount of normal saline; 30 days after administration, the mice in each group were anesthetized (1% sodium pentobarbital 25mg / kg) and blood was collected from the canthus (or from the heart), placed in a sodium heparin anticoagulant tube, centrifuged at 4°C and 4000rpm for 10min, and plasma was separated, and the supernatant was taken into a 1mL EP tube; the livers of mice in each group were collected at the same time. A portion of the liver tissue was used for hematoxylin-eosin (HE) staining, and the specific steps were as follows: (1) After the liver tissue was fixed, it was embedded in paraffin and then sliced; (2) the slices were routinely dewaxed with xylene and hydrated with different levels of ethanol; (3) hematoxylin staining was performed for 3 to 5 minutes, washed with water several times, and then dried; (4) rapid differentiation was performed in 1% hydrochloric acid ethanol, and washed with water several times; (5) soaked in tap water for 15 minutes and then dried; (6) placed in eosin staining solution for 2 minutes; (7) routine dehydration and transparency; (8) sealing and microscopic examination; a portion was used for digestion and ICP was used to detect copper ion concentration.

[0051] The results are as follows Figure 4 As shown: Figure 4 A and B in the figure show that the HA@C3N4-treated group can effectively remove the copper ion content in the blood and liver tissue of mice; Figure 4 C in Figure 3 shows that the H&E staining results showed that there was no obvious damage to the liver tissue in the HA@C3N4-treated group.

[0052] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A method for preparing polymer-modified C3N4 nanoparticles, characterized in that The steps include: (1) Using water as a medium, hyaluronic acid and C3N4 are mixed; (2) Solid-liquid separation, the solid obtained is polymer-modified C3N4 nanoparticles.

2. The method for preparing polymer-modified C3N4 nanoparticles according to claim 1, characterized in that The following steps are also included: (3) The solid obtained in step (2) is washed with water and separated into solid and liquid, and the obtained solid is polymer-modified C3N4 nanoparticles.

3. The method for preparing polymer-modified C3N4 nanoparticles according to claim 1 or 2, characterized in that: The hyaluronic acid and the C3N4 described in step (1) are mixed in a mass ratio of 4 to 6:

2.

4. The method for preparing polymer-modified C3N4 nanoparticles according to claim 1 or 2, characterized in that: The amount of water used in step (1) is calculated based on the ratio of water to hyaluronic acid of 8-12 mL:50 mg.

5. The method for preparing polymer-modified C3N4 nanoparticles according to claim 1 or 2, characterized in that: The water described in step (1) is deionized water; The mixing in step (1) is stirring for 8 to 16 hours; The solid-liquid separation method in step (2) is centrifugation.

6. The method for preparing polymer-modified C3N4 nanoparticles according to claim 5, characterized in that: The stirring speed is 400 to 600 rpm; The centrifugal condition is 10000-12000 rpm for 15-30 min.

7. The method for preparing polymer-modified C3N4 nanoparticles according to claim 2, characterized in that: The water described in step (3) is ultrapure water; The number of washing steps in step (3) is 1 to 3 times; The solid-liquid separation method in step (3) is centrifugation.

8. A polymer-modified C3N4 nanoparticle, characterized in that: The method is obtained by the preparation method according to any one of claims 1 to 7.

9. Use of the polymer-modified C3N4 nanoparticles according to claim 8 in the preparation of a drug for treating copper metabolism disorders.

10. Use of the polymer-modified C3N4 nanoparticles according to claim 9 in the preparation of a drug for treating copper metabolism disorders, characterized in that: The copper metabolism disorder is hepatolenticular degeneration.